Granules India Ltd (BSE: 532482, NSE: GRANULES) has begun supplies of finished dosages to a large multinational pharmaceutical company. The multi-year agreement targets the purchase of in excess of 1.5 billion doses on an annualized basis. This annualized demand represents upwards of 25% of the Company's finished dosage capacity. Commenting on the deal, Mr.C.Krishna Prasad, Managing Director stated, "We are excited to take this next step forward as it validates our vertically-integrat Strong on Financials, Low PE leaves upside for Re-rating the stock Granules India Ltd., a fully backward integrated formulation manufacturer, announced financial results for its fiscal year 2010 third quarter ended December 31, 2009. On a consolidated basis, Granules posted revenue of Rs. 122.40 Cr., an increase of 24.7% over the same period last year and a net profit of Rs. 6.56 Cr.
"This was a record setting quarter due to strong performance from all our divisions. I am particularly excited about our formulation division, which continues to grow rapidly and now comprises over 9% of our sales. This division will ramp up significantly over the next few quarters as we commence work on several key contracts" said C. Krishna Prasad, Managing Director of Granules. About Granules India Ltd., Granules India Ltd. is a fully integrated pharmaceutical manufacturer. The Company manufactures several strategic Active Pharmaceutical Ingredients (APIs) and multiple Pharmaceutical Formulation Intermediates (PFIs), which are distributed in over 50 countries. The Company has recently forayed into the manufacturing of finished dosages with a plant that has a capacity of 6 billion tablets per annum, scalable to 12 billion tablets. This facility will allow Granules to offer products across the value chain. Safe Harbor Statement: Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints. Nothing in this article is, or should be construed as, investment advice. |
__._,_.___
*****************************************
http://in.groups.yahoo.com/group/investwise/
INVESTMENTS IN INDIA
We are low-risk, long-term investors.
Stocks, mutual funds and the entire investment gamut. Only financing/investment avenues in India will be discussed.
For any assistance, questions or improvement ideas, contact investwise-owner@yahoogroups.co.in
****************************************************************
NEW! ==== Check our LINKS and FILES sections for a world of information. REGULARLY UPDATED.
NEW! ==== Check "Tracklist" in Links and Files sections for Investment Ideas.
****************************************************************
http://in.groups.yahoo.com/group/investwise/
INVESTMENTS IN INDIA
We are low-risk, long-term investors.
Stocks, mutual funds and the entire investment gamut. Only financing/investment avenues in India will be discussed.
For any assistance, questions or improvement ideas, contact investwise-owner@yahoogroups.co.in
****************************************************************
NEW! ==== Check our LINKS and FILES sections for a world of information. REGULARLY UPDATED.
NEW! ==== Check "Tracklist" in Links and Files sections for Investment Ideas.
****************************************************************
.
__,_._,___
No comments:
Post a Comment